We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Protein synthesis
- Interference sites for protein synthesis
- David versus Goliath
- Drug targets on 16S rRNA
- 30S-antibiotic structure (1)
- 30S-antibiotic structure (2)
- Drug targets on 23S rRNA
- 50S-antibiotic structures
- Initiation inhibitors
- Kasugamycin history
- 30S-Kasugamycin structure
- Kasugamycin primary binding site (1)
- Kasugamycin primary binding site (2)
- Kasugamycin resistance
- Alternative conformations for helix 45
- Indirect resistance mechanism
- Kasugamycin secondary binding site
- Kasugamycin: 70S versus 30S
- Kasugamycin binds in mRNA pathway
- Kasugamycin inhibits tRNA binding to 30S
- Mechanism of kasugamycin action
- Inhibitors of initiation: edeine and pactamycin
- 30S-edeine structure
- 30S-pactamycin structure
- Pactamycin inhibits translocation
- Relative binding sites of initiation inhibitors
- Thiostrepton
- Chemical structure of thiostrepton
- Thiostrepton binding site on 23S rRNA
- 50S-thiostrepton structure
- 50S binding site of thiostrepton
- Thiostrepton interaction
- Native L11 position
- Free versus bound thiostrepton
- Minimal thiostrepton fragment
- Interaction of DHP
- Thiostrepton inhibits EF-G dependent Pi release
- Cryo-EM of 70S-EF-G complex
- Stalk base movement upon EF-G binding
- Thiostrepton allows initial binding of EF-G
- Thiostrepton prevents EF-G accommodation
- Thiostrepton resistance in bacteria
- Thiostrepton resistance in eukaryotes
- Peptidyltransferase (PTF) inhibitors
- Binding site of PTF inhibitors on 23S rRNA
- Inhibition of PTF activity
- Chemical structure of chloramphenicol
- 50S-chloramphenicol structure
- Peptidyltransferase centre
- Chloramphenicol binding site on 50S
- Chloramphenicol overlap with A-tRNA
- Chemical structures of macrolide antibiotics
- Macrolide binding site on 23S rRNA
- 50S-telithromycin structure
- Telithromycin binds in tunnel
- D50S-Tel versus H50S-Tel
- D50S-Tel versus D50S-Tel new
- New D50S-Tel versus H50S-Tel
- Species specific binding of antibiotics (1)
- Species-specific binding of antibiotics (2)
- Summary
- Bibliography
Topics Covered
- Overview of antibiotics that target the ribosome
- Different mechanisms by which translation initiation inhibitors, such as kasugamycin and edeine, perturb initiator tRNA binding
- Structural insight into how the thiopeptide class of antibiotics, such as thiostrepton and micrococcin, inhibit stable binding of translation factors, such as EF-G, to the ribosome
- Mechanism by which drugs, such as chloramphenicol and macrolides inhibit the peptidyltransferase reaction
- How species specific differences in antibiotic interaction sites between different organisms can have a dramatic influence on drug binding
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Wilson, D. (2008, May 15). Antibiotic inhibition of ribosome function [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 5, 2024, from https://doi.org/10.69645/SYZK1506.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Daniel Wilson has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.